Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice by Yasuda, Y et al.
Erythropoietin (Epo) from the kidney and liver is involved in a well-
recognized function, erythropoiesis (Kranz, 1991; Jelkman, 1992;
Youssoufian et al, 1993; Wu et al, 1995; Lin et al, 1996; Masuda
et al, 1999). Epo supports the survival of erythroid precursor cells
and stimulates their proliferation and differentiation by binding to
its specific receptor (EpoR), which belongs to a family of cytokine
receptors that have no tyrosine kinase domain. The mitogenic action
of Epo appears to be caused by Epo-induced homodimerization of
EpoR and the subsequent activation of JAK2 through tyrosine phos-
phorylation, ultimately leading to activation of a transcriptional
factor, STAT5 (Youssoufian et al, 1993; Ihle, 1995). Recently, Epo
has been shown to be produced in the brain by astrocytes and to
protect neurons from ischaemic damage via EpoR expressed in
neurons (Sadamoto et al, 1998; Sakanaka et al, 1998). The neuro-
protective action of Epo is manifested by a reduction of nitric oxide
neurotoxicity (Sakanaka et al, 1998) but its precise mechanism is
not known. Production of Epo at these 3 sites (kidney, liver
and brain) is hypoxia-inducible (Porter and Goldberg, 1993;
Bunn and Poyton, 1996; Guillemin and Krasnow, 1997; Wenger and
Gassmann, 1997; Ratcliffe et al, 1998; Semenza, 1998). 
Vascular endothelial cells express EpoR and respond to Epo
in vitro. EpoR mRNA is expressed in endothelial cells from
various sources (Anagnostou et al, 1994; Yamaji et al, 1996). Epo
stimulates proliferation and migration of endothelial cells
(Anagnostou et al, 1990) and also in vitro angiogenesis (Carlini
et al, 1995). Epo signalling as a mitogen of endothelial cells is
conducted via tyrosine phosphorylation of proteins including
phosphorylation of transcription factor STAT5, which is similar to
that occurring in erythroid cells (Haller et al, 1996). More recently
Epo has been shown to induce a potent angiogenic response in the
chick chorioallantoic membrane (Ribatti et al, 1999). We have
presented in vivo evidence that Epo plays a critical role in mouse
uterine angiogenesis via EpoR expressed in vascular endothelial
cells of the uterine endometrium (Yasuda et al, 1998). A new site
for Epo production exists in the uterus where Epo production is
induced by 17b-estradiol (E2) (Yasuda et al, 1998). In contrast to
that in the liver, kidney and brain, Epo production by the uterus is
not hypoxia-inducible in the absence of E2 but it gains hypoxia-
inducibility in the presence of E2. We have also found that the
mouse ovary expresses Epo mRNA (Yasuda et al, 1998). 
On the basis of the finding that female reproductive tissues
produce Epo, we speculated that Epo signalling might contribute
to the development and the progression of malignant tumours of
these organs. Previously we reported that all malignant tumour
specimens derived from the ovary and uterus expressed Epo
mRNA and EpoR. The cells producing Epo mRNA were not
identified, but EpoR was expressed in both malignant cells and
vascular endothelial cells. Withdrawal of Epo signalling through
injection of anti-Epo antibody or a soluble form of EpoR (sEpoR),
both of which are capable of binding with Epo, into surgically
resected tumour blocks induced apoptotic death of malignant cells
and regression of vessels in vitro, suggesting that Epo, in addition
to its direct mitogenic effects on malignant cells, may facilitate
tumour growth via an increase in the vascular supply. Encouraged
by these in vitro results, we studied the effects of Epo-signal with-
drawal on tumours in vivo. Here we show that the blockade of Epo
signalling in xenografts of uterine and ovarian tumours in nude
mice results in clearance of malignant cells and feeding vessels,
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Summary We have recently shown that malignant tumours from the ovary and uterus expressed erythropoietin (Epo) and its receptor (EpoR),
and that deprivation of Epo signal in tumour blocks induced death of malignant cells and capillary endothelial cells in vitro (Yasuda et al,
submitted). These in vitro results prompted us to examine the effect of Epo-signal withdrawal on tumours in vivo. RT-PCR analysis
demonstrated the expression of mRNAs for Epo and EpoR in the transplants of uterine and ovarian tumours in nude mice. Then we injected
locally anti-Epo antibody or soluble form of EpoR into the transplants. At 12 h, 1, 7 or 14 days after the injection, all transplants were resected
and examined macro- and microscopically. Tumour size was reduced in Epo signal-deprived transplants. Immunohistochemical examinations
revealed destruction of Epo-responding malignant and capillary endothelial cells through apoptotic death. The degree of tumour regression
correlated well with the dose and frequency of the injections. Control xenografts with saline injection or needle insertion showed well-
developed tumour masses. This Epo response pathway will have profound implications for our understanding of the development and
progression of malignant tumours and for the use of Epo-signal deprivation as an effective therapy. © 2001 Cancer Research Campaign
http://www.bjcancer.com
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The experiments described in this paper were performed according to UKCCR
Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).
http://www.bjcancer.comsuggesting that Epo-signal interception may be a novel therapy for
malignant tumours of female reproductive organs. 
MATERIALS AND METHODS 
Animals 
Hairless female mice (Balb/c, Jcl-nu) were purchased from Clea
Inc, Japan, at 5 weeks of age, placed one by one in aseptic cham-
bers and given sterilized pellets and water ad libitum in a specific
pathogen-free room. At 6 weeks of age or older, they were inocu-
lated with a piece of cancer specimen or transplant. 
Transplantation 
Resected tumour specimens were put into a-MEM (Gibco) with
10% fetal calf serum containing streptomycin (100 m1 ml21) and
penicillin (100 IU ml21) at 4˚C and cut into small pieces. The
patients gave informed consent for these specimens to be used for
the experiments. Transplants were derived from 14 primary adeno-
carcinomas (ADC) and 3 squamous cell carcinomas (SCC) of the
cervix, and 2 ovarian ADC; secondary tumours were from 1
primary ovarian ADC. 
Under deep anaesthesia an incision was made in the intrascapular
region of the mouse and a piece of primary or secondary tumour
measuring approximately 5 3 5 3 5 mm was inserted subcuta-
neously. The incision was sutured and sprayed with Novactan. The
length and width of the implants were measured
3 times a week. Tumour growth was calculated according to the
Battle Memorial Institute Protocol (Ovejara et al, 1978). 
RT-PCR amplification 
To confirm the expression of mRNAs for Epo and EpoR in the
xenografts, 5 tumours from ovarian and uterine ADC or SCC were
transplanted. When their diameter had reached 12–15 mm, they
were extirpated and frozen in liquid nitrogen. The frozen materials
were homogenized to extract total RNA. 
Total RNA was prepared with the RNA Extraction kit
(Amersham). The RT reaction was performed with an avian
myeloblastosis virus (AMV) reverse transcriptase, random
nanomer primer (Takara) and 1 mg of each RNA in a total volume
of 20 ml with the use of a TaKaRa RNA LAPCRTM Kit (AMV) Ver.
1.1. PCR primer of Epo, EpoR and b-actin were those described
previously (Yasuda et al, 1993). PCR cycles and conditions for
denaturation, annealing, and elongation were 28 cycles, 30 at
94˚C, 30 s at 60˚C, and 1.5 min at 72˚C of Epo; 30 cycles, 1 min at
94˚C, 2 min at 55˚C and 3 min at 72˚C of EpoR and b-actin. The
amplified DNA was fractionated by electrophoresis on a 12%
agarose gel (BioProduct) and stained with ethidium bromide. 
Treatment 
Injection materials 
Anti-Epo monoclonal antibody, R2, a gift from the Snow Brand
Milk Product Co. (Tokyo, Japan) (Goto et al, 1989), and sEpoR
prepared by the methods of Nagao et al (1992) were dissolved in
saline (Ohtsuka, Tokyo, Japan). Saline was used as the control
solution. To these solutions Evans blue dye (Merck, Darmstadt,
Germany) was added to make a final concentration of 0.025% for
colouring. 
Injection 
When the transplanted tumours had grown larger than 3 times their
initial size, 0.2 ml of R2 or sEpoR was injected 3 or 4 times at
intervals of 60 min, 6 h or 12 h into each tumour (Table 1). In
some control transplants a needle was inserted at the same
intervals. The type of transplant, concentrations of R2 or sEpoR
and injection schedule are listed in Table 1. 
Macroscopy 
At 12 hours or 1, 7 and 14 days after treatment, the tumour masses
were resected under deep anaesthesia. After examination under a
dissecting microscope, the tumours were fixed in Zamboni solu-
tion and processed for immunostaining. 
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Table 1 Regression of uterine and ovarian tumours transplanted in nude mice injected with anti-Epo antibody or sEpoR 
Experiment Type of tumour No. of mice Treatment schedulea Extirpation Tumour size
transplanted  transplanted Injected Concn. mg ml-1 Injection After last at extirpation
(age of patient)  time (h) injection (day) (%)b
1 ADC-endometrium 1 R2 0.125 0, 6, 12  1 66 
2 (57) 1 R2 0.25 0, 6, 12 1 63 
3 ADC-endometrium 2 R2 8 0, 1, 2 0.5  61 
4 (64) 2 R2 16 0, 1, 2 0.5 34 
5 SCC-cervix 3 R2 16 0, 1, 2 1 17 
(69) 
6 ADC-cervix 3 sEpoR 0.2 0, 1, 2 1  65 
(38) 
7 ADC-ovary 2 sEpoR 0.2 0, 1, 2, 3 7  48 
secondary 
8 ADC-ovary 2 R2 8 0, 1, 2, 14 14 23c, 11 
primary (78) 
aWhen the transplanted tumours grew larger than 3 times their initial size, anti-Epo monoclonal antibody (R2) or soluble form of EpoR (sEpoR) was injected
according to the treatment schedule indicated. Saline was injected in the control mice bearing the transplanted tumours in the same schedule. bTumour size
relative to that just before the injection. When two or three mice were transplanted with individual tumours (Exps 3–8), average tumour sizes are shown.
cTumour size 7 days after injection. Immunohistochemistry 
After cryoprotection, the specimens were cut in 7 mm slices on a
cryostat (Leica, Germany) and processed for immunostaining as
described previously (Yasuda et al, 1992). The following antibodies
were used as the primary antibodies; anti-EpoR (Yasuda et al, 1992)
(1/500 dilution), anti Factor-VIII (FVIII) (DAKO) (1/200 dilution),
and anti-mouse macrophages (F4/80, Serotec) (1/200 dilution). The
staining specificity of EpoR antibody was confirmed with the use of
the antibody preabsorbed with sEpoR. No antigens were available
for FVIII and F4/80, so rabbit IgG (1/200 dilution) (Cappel) and rat
IgG (1/200 dilution) (Zymed) were used, respectively. To detect
apoptosis, TdT assay was done with a TdT assay kit (Oncor,
Gaitherberg, MD). The positive control for TdT assay was
confirmed on sections of adult rat testis, and the negative control
was performed on sections of rat testis without TdT enzyme (data
not shown). In all tumours, 15 to 20 sections from 3 to 5 thick slices
of each specimen were stained with each antibody, and 4 to 6
sections from a tumour were used for TdT assay. The pathological
features in each specimen were graded in sections stained with each
antibody or subjected to TdT assay; they are summarized in Table 2. 
Capillary counting 
Sections of all specimens were stained with anti-FVIII antiserum.
Cross- and longitudinally sectioned capillaries were counted with
an eye-piece ocular micrometer in 100 areas of each specimen
(2.85 3 1022 mm2) in sections separated by 21 mm. 
RESULTS 
Transplant 
A total of 45 cancer fragments were implanted, and 36 primary
and secondary transplants grew successfully. One of the ovarian
xenografts grew large enough to be retransplanted successfully. It
was extirpated, cut into fragments, and implanted into 5 other nude
mice 4.5 months after the first implantation. One transplant
became necrotic at 5 months and was excluded from the experi-
mental procedures. 
Expression of Epo and EpoR mRNA 
5 transplants derived from 1 cervical SCC, 3 endometrial ADC
(ADCE) and one ovarian ADC (ADCO) were examined with RT-
PCR, and the results are shown in Figure 1. Xenograft of SCC-59
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Table 2 Pathological features in xenografts injected with R2, sEpoR or saline or receiving needle insertion
Experimenta No. of Destroyed foci Intact Endothelial Apoptosis Phagocyte
(type of tumour, tumours malignant foci degeneration infiltration
injection, mg ml–1) examined
Uterus 1 (ADC-E, R2, 0.125) 1 +2 +1  +1 +2 +2 
2 (ADC-E, R2, 0.25) 1 +3 +1 +2 +2 +3 
(ADC-E, saline) 1 +1 +2, +3 2 +1 +1 
3 (ADC-E, R2, 8) 2 +5, +5 2,2 +3,+3 +4, +5 +5,+5 
4 (ADC-E, R2, 16) 2 +7,+5 2,2 +5,+5 +5, +5 +5, +5 
(ADC-E, saline) 2 +1, +2 +3, +3 2,2 +1, +1 +2, +2 
(ADC-E, needle) 1 +1 +3 2 +2 +2 
5 (SCC-C, R2, 16) 3 +7, +7, +7 2,–,– +7, +7, +7 +5, +5, +5 +5, +5, +5 
(SCC-C, saline) 3 +2, +2, +2 +3, +2, +3 –, –,– –, +2, +1 +1, +1, +1 
(SCC-C, needle) 1 +1 +2 –  +1 +1 
6 (ADC-C, sEpoR, 0.2) 3 +7, +7, +7  –,–,– +7, +7, +5 +5, +5, +5 +3, +3, +3 
(ADC-C, saline) 2 +1, +1 +5, +3 –,– +2, 2 +2, +1 
Ovary  7 (2nd, sEpoR, 0.2) 2 +3, +3 +1, +1b +2, +2 +3, +3 +5, +5 
(2nd, saline) 1 –c ¨–
(2nd, needle) 1 +1 +5 – +1 +2 
8 (ADC-O, R2, 8) 2 +3, +3 +1b, +1 +3, +3 +3, +3 +5, +5 
(ADC-O, saline) 2 +1, +2 +5, +5 –,– +1,2 +3,+2 
aExperimental number corresponds to that in Table 1. b, scab over the lesion, c, total necrosis. Plus (+) or minus (-) indicates presence or almost none.
Number after plus means grade of each phenomenon among tumours of the same origin; +7 is most severely damaged, and +1, weakest or smallest foci;
Phagocytes include neutrophils, monocytes and macrophages; ADC-C, cervical adenocarcinoma; ADC-E, endometrial adenocarcinoma; ADC-O, ovarian
adenocarcinoma; SCC-C, cervical squamous cell carcinoma; 2nd, secondary ovarian tumour; R2, antibody against erythropoietin; sEpoR, soluble form of
erythropoietin receptor.
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Figure 1 Detection of Epo- and EpoR-transcript in xenografts of ovarian
and uterine cancer by RT-PCR. All xenografts express Epo and EpoR
mRNAs. ADCE, ADCO and SCC: origin of transplants; endometrial, ovarian
ADC and squamous cell carcinoma. The number after the abbreviation
means age of a patient. RNA—: no RNA; RT—: no reverse transcriptase;
UT-7: megakaryoblast cell line; HepG2: hepatoma cell line showed high expression of Epo mRNA, and the grafts of ADCE-
55, ADCE-48, ADCE-66 and ADCO-62 showed weak expression.
HepG2 is a human hepatoma cell line that produces Epo (Maxwell
et al, 1993). Epo mRNA was clearly detected in HepG2. 3 trans-
plants of ADCE-48, ADCE-66 and ADCO-62 showed strong ex-
pression of EpoR mRNA, and the 2 transplants of ADCE-55 and
SCC-59 showed weak expression. UT-7 is a megakaryoblast cell
line which expresses EpoR mRNA (Komatsu and Fujita, 1993).
EpoR mRNA was strongly expressed in UT-7. All samples showed
unchanged b-actin mRNA. 
Tumour growth 
Growth curves of all grafts were plotted, and the degree of tumour
regression after injection of R2 or sEpoR was calculated from each
growth curve. Table 1 shows the injection schedule and the tumour
regression induced by injection of R2 or sEpoR that can deplete
Epo. Injection of R2 or sEpoR reduced the size of all transplanted
tumours. After 12 h of treatment the tumours injected 3 times with
16 mg ml21 of R2 had shrunk in size to about one half of the size of
those injected with 8 mg ml21 of R2 (Exps 3 and 4 in Table 1). On
day 14 after the last injection of 8 mg ml21 of R2, the tumours were
half the size they measured on day 7 (Exp. 8 in Table 1). The
control tumours injected with saline were 93 to 95% of their ori-
ginal size or even larger than before injection. Needle insertion
caused no regression. Therefore, the reduction of tumour size
appears to be dose-dependent and also to depend on the interval
since the last injection of the material disrupting Epo-signal trans-
duction. 
Macroscopy 
All 35 xenografts were examined. Typical effects of R2 or sEpoR
on tumours are shown in Figure 2. At 24 h after injection of R2
compact tumour masses were difficult to detect under the tumour
capsule (Figure 2A), while the control tumour had small or large
compact tumour masses with or without small holes or necrotic
foci (Figure 2B). The transplants at 7 or 14 days after the injection
of R2 (Figure 2C) or sEpoR (Figure 2E) had few fresh compact
tumour masses under the capsule beneath the scab. Some twigs of
capillaries were detectable in tumours injected with sEpoR (Figure
2E) and almost all twigs disappeared in those injected with R2
Destruction of xenografts of malignant tumours 839
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Figure 2 Interior or cut surface of resected tumours. (A) Xenograft of SCC one day after injection of R2 (one of the grafts in Exp. 5 in Table 1). Note
destruction of tumour masses with holes and many pale edges (arrows). (B) Control graft of (A) injected with saline (one of the controls in Exp. 5 in Table 2).
Note fresh masses with central hole (arrow). Arrowhead points to vessels near the capsule. (C) Xenograft of primary ovarian ADC 14 days after injection of R2
(one of the grafts in Exp. 8 in Table 1). Note thick scab and large defect of tumour masses leaving fibrous tissues with many holes. (D) Control xenograft of (C)
(one of the controls in Exp. 8 in Table 2). Note compact tumour masses under thin capsule and many capillaries in the tumour (small arrow) and in the capsule
(large arrow). (E) Xenograft of secondary ovarian ADC 7 days after injection of sEpoR (one of the grafts in Exp. 7 in Table 1). Note covering scab (arrows) and
destroyed tumour masses leaving membranous tissues with broken capillary twigs. Central blue spot is Evans blue dye deposit. (F) Control xenograft of (E)
inserted with needle only (control in Exp. 7 in Table 2). Note compact tumour masses, central pus (arrow) and vessels. (A) and (B), (C), (D) and (F), are at the
same magnification. Scale bar, 100 mm 840 Y Yasuda et al 
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Figure 3 Localization of EpoR in xenografts and the staining specificity of each antibody. (A–C) were stained with anti-EpoR; (D), with EpoR antiserum
preabsorbed with sEpoR; (E), with rabbit IgG; (F), with rat IgG; (G), adapted to TdT assay. (A) Xenograft of ADC-E (Exp. 4 in Table 2). Note immunoreactive
EpoR in degenerating glandular epithelium (arrows), and recruitment of neutrophils (small arrows). (B) Control of (A) with needle insertions. Note
immunoreactive EpoR in well-developed glandular epithelium (arrows) and vascular endothelium (small arrows). (C) Xenograft of ADC-O (control of Exp. 7 in
Table 2) shows immunoreactive malignant cells (arrows) and capillary endothelium (small arrows). (D) Another sections shown in (C). No immunoreactive EpoR
is discernible. (E) Xenograft of ADC-O shown in Figure 2 (D). Note no positive stainability in vascular endothelium (arrows). (F) Xenograft of ADC-O shown in
Figure 2 (E). Note no stainable monocytes and macrophages (arrows). (G) Rat testis. Note positive reaction in spermatogonia (arrows). (A) and (B), and (C–F)
are at the same magnification. Scale bar, 50 mm 
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Figure 4 Destructive processes of xenografts of ovarian tumour. (A–C): xenografts of Exp. 7 in Table 2; (E–G) and (H): xenograft of control of Exp. 8 in Table
2. (A) and (D) were stained with anti-FVIII; (B) and (F), subjected to TdT assay; (C) and (G), with anti-F4/80; (D) and (H), with anti- EpoR antibody. (A) Shows
destruction of malignant tissues in left half containing small or large mononuclear cells (arrows), and a few capillaries (small arrows). (B) Note many apoptotic
cells (arrows) in both malignant tissues including endothelial cell (smallest arrow) and destructive regions (small arrows). (C) Note many monocytes and
macrophages (arrows) and fragmented nuclei (small arrows). (E) Shows well-developed vascular nets. Arrows point to endothelial cells. (F) Note less numerous
apoptotic cells than in (B). (G) Note sporadic distribution of macrophages (arrows). (D) Xenograft (Exp. 8 in Table 2) shows little malignant spots (arrows)
surrounded with fibrous connective tissues. Note strong EpoR immunoreactivity of dying malignant cells (small arrows) in corresponding rectangle shown in
Figure 2 (C). The scab covering (asterisks) was melted away during staining procedures. (H) Control of (D). Note malignant tissues with EpoR immunoreactivity.
All panels except (D) are at the same magnification. Scale bar, 50 mm 
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H(Figure 2C). The control tumours that received saline injection
(Figure 2D) or needle insertion (Figure 2F) had compact fresh
tumour masses with vessels or pus-like material in the middle of
the tumour (Figure 2F). 
Microscopy 
The grafts injected with high or low doses of R2 or sEpoR showed
the destruction of characteristic malignant structures to various
degrees (Table 2), and such alterations were detectable 12 h after
injection (Figure 3A): in the grafts of ADCE (Exp. 4 in Tables 1
and 2) the glandular epithelial cells that showed positive EpoR-
immunoreactivity were destroyed, then invaded with neutrophils
leading to disappearance of glandular epithelial cells (Figure 3A).
The needled control graft (control of Exp. 4 in Table 2) showed
well-developed large or small glandular structures in which
EpoR-immunoreactivity was detectable in glandular epithelial
and vascular endothelial cells (Figure 3B). 7 days after needle-
insertion, the graft (control of Exp. 7 in Table 2) still had well-
developed malignant tissues expressing EpoR immunoreactivity
(Figure 3C). The staining specificity of the EpoR antibody was
confirmed in other sections shown in Figure 3C (Figure 3D). The
staining specificity for FVIII and F4/80 antibody was confirmed in
the sections of each graft, control and Exp. 8 in Table 2, respec-
tively and is shown in Figures 3 E and 3 F. The positive control for
TdT assay was confirmed in the spermatogonia of the rat testis
(Figure 3G). 
The grafts injected with sEpoR (Exp. 7 in Table 2) showed
severe destruction of malignant foci with fewer vascular nets
(Figure 4A), many more neutrophils, monocytes and macrophages
(Figure 4A, C) and a far denser distribution of cells undergoing
apoptotic death (Figure 4B) than those seen in the grafts injected
with saline (control of Exp. 8 in Table 2) (Figure 4D–F). 
The grafts injected with R2 (Exp. 8 in Table 2) were occupied
by connective tissue-like materials containing mononuclear large
and small cells and many fibrous cells under thick scab coverings
14 days after the injection (Figure 4G). Dying malignant cells
were sporadically discernible, and some of them expressed
strong EpoR immunoreactivity (Figure 4G). The control grafts
injected with saline (control of Exp. 8 in Table 2) showed well-
developed malignant structures with EpoR immunoreactivity
(Figure 4H). 
Effects on vasculogenesis 
To clarify the dependency of vasculogenesis on Epo signalling in
the grafts, we counted the number of cross-and longitudinally
sectioned capillaries. The results are shown in Figure 5. The
number of capillaries was comparable among the specimens
before transplant and in the control grafts with saline injection or
needle insertion, but it was significantly lower in the grafts that
received injections of R2 or sEpoR (P < 0.001). 
DISCUSSION 
Withdrawal of Epo signalling in the grafts of female reproduc-
tive organ-derived tumours that expressed mRNAs for Epo and
EpoR by the local injection of R2 or sEpoR caused marked
degeneration of malignant cells and disappearance of capillaries
leading to destruction of the tumour masses. The present results
together with the in vitro findings reported previously strongly
suggest that not only proliferation and/or survival of malignant
cells in the female reproductive organ-derived grafts but also
capillary formation in the grafts, which could be essential for the
development of tumour progression, is at least partly attributable
to Epo signalling. The present study also revealed the process of
elimination of degenerated and dead malignant components by
the host’s immune and inflammatory cells, leading to repair of
the lesion. 
The characteristic features of degeneration seen in the tumours
were extremely strong expression of EpoR in dying cells, and
apoptotic death of the malignant cells. These phenomena were
seen in all grafts injected with R2 or sEpoR and sporadically in the
degenerating sites of the control grafts. This pattern of tissue
degeneration was also detected in the in vitro cultured tumours
injected with sEpoR or R2. In the cell line HCD57, the survival of
which depends entirely on Epo signalling, EpoR is expressed
intensely upon deprivation of Epo (Sawyer et al, 1993). The
deprivation of Epo from the culture medium of the cell line
appears to reduce the receptor internalization, resulting in a high
expression of EpoR in the cytoplasmic membrane. The same is
likely to be true for the grafts injected with R2 or sEpoR that
decreases the amount of Epo available for cellular EpoR. 
Infiltration of a large number of cells including neutrophils,
macrophage and monocytes was also seen in the degenerated and
amorphous regions of experimental grafts 12 h after the injection.
Additionally, many fibrous cells were seen under the scab cover-
ings 7 and 14 days after the treatment. These cells are likely to
contribute to the repair of the destroyed regions. 
In conclusion, deprivation of Epo signalling caused by the injection
of R2 or sEpoR into xenografts of malignant uterine and ovarian
tumours induces the destruction of Epo-expressing malignant
tumours and capillaries. The present results validated our previous
findings that interception of Epo signalling in blocks of cancer speci-
mens from female reproductive organs led to their destruction through
the injection of R2 or sEpoR in vitro (in submission). Our results may
842 Y Yasuda et al 
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have implications for the treatment of female reproductive cancers
characterized by the operation of Epo signal transduction. 
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